187 related articles for article (PubMed ID: 34193056)
1. Study rationale and design of a study of EMPAgliflozin's effects in patients with type 2 diabetes mellitus and Coronary ARtery disease: the EMPA-CARD randomized controlled trial.
Gohari S; Reshadmanesh T; Khodabandehloo H; Fathi M; Ahangar H; Arsang-Jang S; Ismail-Beigi F; Ghanbari S; Dadashi M; Muhammadi MJ; Gohari S; Ghaffari S
BMC Cardiovasc Disord; 2021 Jun; 21(1):318. PubMed ID: 34193056
[TBL] [Abstract][Full Text] [Related]
2. Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes.
Sarak B; Verma S; David Mazer C; Teoh H; Quan A; Gilbert RE; Goodman SG; Bami K; Coelho-Filho OR; Ahooja V; Deva DP; Garg V; Gandhi S; Connelly KA; Yan AT
Cardiovasc Diabetol; 2021 Oct; 20(1):200. PubMed ID: 34607574
[TBL] [Abstract][Full Text] [Related]
3. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
[TBL] [Abstract][Full Text] [Related]
4. Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.
Levine MJ
Curr Diabetes Rev; 2017; 13(4):405-423. PubMed ID: 27296042
[TBL] [Abstract][Full Text] [Related]
5. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
Ridderstråle M; Svaerd R; Zeller C; Kim G; Woerle HJ; Broedl UC;
Cardiovasc Diabetol; 2013 Sep; 12():129. PubMed ID: 24007456
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study.
Shigiyama F; Kumashiro N; Fuchigami A; Hirose T
Cardiovasc Diabetol; 2018 Jun; 17(1):86. PubMed ID: 29895330
[TBL] [Abstract][Full Text] [Related]
7. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
Hiruma S; Shigiyama F; Hisatake S; Mizumura S; Shiraga N; Hori M; Ikeda T; Hirose T; Kumashiro N
Cardiovasc Diabetol; 2021 Feb; 20(1):32. PubMed ID: 33530982
[TBL] [Abstract][Full Text] [Related]
8. Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial.
Ceriello A; Ofstad AP; Zwiener I; Kaspers S; George J; Nicolucci A
Cardiovasc Diabetol; 2020 Oct; 19(1):176. PubMed ID: 33050931
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin.
Tanaka A; Shimabukuro M; Teragawa H; Okada Y; Takamura T; Taguchi I; Toyoda S; Tomiyama H; Ueda S; Higashi Y; Node K;
Cardiovasc Diabetol; 2021 Jul; 20(1):160. PubMed ID: 34332584
[TBL] [Abstract][Full Text] [Related]
10. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
[TBL] [Abstract][Full Text] [Related]
11. Effects of dapagliflozin vs vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease: a randomised study.
Phrommintikul A; Wongcharoen W; Kumfu S; Jaiwongkam T; Gunaparn S; Chattipakorn S; Chattipakorn N
Br J Clin Pharmacol; 2019 Jun; 85(6):1337-1347. PubMed ID: 30767253
[TBL] [Abstract][Full Text] [Related]
12. Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study.
Gaborit B; Ancel P; Abdullah AE; Maurice F; Abdesselam I; Calen A; Soghomonian A; Houssays M; Varlet I; Eisinger M; Lasbleiz A; Peiretti F; Bornet CE; Lefur Y; Pini L; Rapacchi S; Bernard M; Resseguier N; Darmon P; Kober F; Dutour A
Cardiovasc Diabetol; 2021 Mar; 20(1):57. PubMed ID: 33648515
[TBL] [Abstract][Full Text] [Related]
13. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.
Bosch A; Ott C; Jung S; Striepe K; Karg MV; Kannenkeril D; Dienemann T; Schmieder RE
Cardiovasc Diabetol; 2019 Mar; 18(1):44. PubMed ID: 30922297
[TBL] [Abstract][Full Text] [Related]
14. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial.
McGuire DK; Zinman B; Inzucchi SE; Wanner C; Fitchett D; Anker SD; Pocock S; Kaspers S; George JT; von Eynatten M; Johansen OE; Jamal W; Mattheus M; Elsasser U; Hantel S; Lund SS
Lancet Diabetes Endocrinol; 2020 Dec; 8(12):949-959. PubMed ID: 33217335
[TBL] [Abstract][Full Text] [Related]
15. Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers.
Gessner A; Gemeinhardt A; Bosch A; Kannenkeril D; Staerk C; Mayr A; Fromm MF; Schmieder RE; Maas R
Cardiovasc Diabetol; 2022 Jan; 21(1):4. PubMed ID: 34991562
[TBL] [Abstract][Full Text] [Related]
16. Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial.
Bonora BM; Vigili de Kreutzenberg S; Avogaro A; Fadini GP
Cardiovasc Diabetol; 2019 Aug; 18(1):106. PubMed ID: 31412874
[TBL] [Abstract][Full Text] [Related]
17. Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes.
Yabe D; Shiki K; Suzaki K; Meinicke T; Kotobuki Y; Nishida K; Clark D; Yasui A; Seino Y
BMJ Open; 2021 Apr; 11(4):e045844. PubMed ID: 33827843
[TBL] [Abstract][Full Text] [Related]
18. Can we go beyond surrogates?
Drexler A
J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
[TBL] [Abstract][Full Text] [Related]
19. Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.
Rau M; Thiele K; Hartmann NK; Schuh A; Altiok E; Möllmann J; Keszei AP; Böhm M; Marx N; Lehrke M
Cardiovasc Diabetol; 2021 Jan; 20(1):6. PubMed ID: 33413355
[TBL] [Abstract][Full Text] [Related]
20. Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial.
Tanaka A; Shimabukuro M; Teragawa H; Okada Y; Takamura T; Taguchi I; Toyoda S; Tomiyama H; Ueda S; Higashi Y; Node K;
Cardiovasc Diabetol; 2021 Jun; 20(1):105. PubMed ID: 34183012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]